Drug Trial Radar · NCT03741127
Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Last checked: Nov 20, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Oct 29, 2018
Primary completion
Aug 2032
Study completion Nov 2032
Sponsor
- Lead sponsor
- Poseida Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- California Institute for Regenerative Medicine (CIRM)
- First posted
- Nov 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.
Conditions
- Multiple Myeloma
Interventions
Rimiducid may be administered as indicatedDrug
Patients who received P-BCMA-101 in a previous trial will be evaluated in this trial for long term safety and efficacy. Rimiducid (safety switch activator) may be administered as indicated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Treatment with P-BCMA-101 through year 15
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
University of California Davis
Davis, California
University of California, San Diego
San Diego, California
University of California San Francisco
San Francisco, California
Colorado Blood Cancer Institute
Denver, Colorado
University of Chicago
Chicago, Illinois
University of Kansas Cancer Center
Westwood, Kansas
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
Johns Hopkins University
Baltimore, Maryland
Wayne State - Karmanos Cancer Institute
Detroit, Michigan
University of Pennsylvania
Philadelphia, Pennsylvania
Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.